Other
Chemoradiotherapy
0
Pipeline Programs↗
40
Active Trials↗
2
Companies Involved↗
Chemoradiotherapy is an early-stage landscape with 0 programs across 2 companies. The most active players are Sanofi, Japan Clinical Oncology Group.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
83
clinical trials
Recruiting22 · 27%
Completed20 · 24%
Unknown status19 · 23%
Not yet recruiting11 · 13%
Active, not recruiting6 · 7%
Terminated3 · 4%
Other2 · 2%
Clinical Trials
Trial Activity
83 trials
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
Recruiting·—·Phase 3·NCT04585490·48 enrolled
Chemoradiotherapy With Surgery Followed by Consolidation Durvalumab
Recruiting·—·Phase 4·NCT06908070·38 enrolled
Clinical Study of Thiopegfilgrastim for Preventing Bone Marrow Suppression in Thoracic Tumor Chemoradiotherapy
Recruiting·—·Phase 2·NCT07205536·30 enrolled
Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.
Recruiting·—·Phase 2·NCT06059261·30 enrolled
Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer
Recruiting·—·Phase 3·NCT04821778·2,000 enrolled
Page 1 of 6
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)